A unique drug for each patient:

a paradigm shift in cancer therapy

By Steven A. Rosenberg

The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.

Free News Analysis

As government shutdown looms, don't lose sight of bigger battle over appropriations, sequestration

By Paul Goldberg

Recent Issues

A unique drug for each patient:

As government shutdown looms, don't lose sight of bigger battle over appropriations, sequestration

In Brief

Allison, Bax, Doudna and Chang receive NAS prizes

Kathy Albain receives first Huizenga Family Endowed Chair at Loyola University Chicago

ACS CAN: Cancer patients should be exempt from possible Medicaid work requirements

ACCC's 2017 survey: cost of treatment is top threat to cancer program growth

Clinical Roundup

Blood test for eight cancer types provides framework for early detection

Study shows screening population for select genes is a cost-effective solution

Polygenic hazard score predicts when men develop prostate cancer

Exelixis and Ipsen announce phase III trial results of Cabozantinib in advanced hepatocellular carcinoma

Drugs & Targets

Foundation Medicine and Pfizer form partnership to develop companion diagnostics

FDA approves addition of overall survival data to Kyprolis

Novartis granted FDA Priority Review for Kymriah for adults with r/r DLBCL

NCI Trials

NCI CTEP-Approved Trials for January

Recent Issues

Renew today!

Subscriber content